Emerging Diseases

Top Story

Merck’s Ebola vaccine, used widely in DRC outbreak, up for FDA approval

September 17, 2019

Read the Perspective from Amesh A. Adalja, MD

In the Journals

Novel drug combination noninferior to meropenem for treating cUTIs

September 12, 2019
A novel combination that includes ceftriaxone, sulbactam and disodium EDTA, or CSE, was noninferior to meropenem for the treatment of complicated UTIs, or cUTIs, caused…
Feature

Q&A: Raising awareness of chronic granulomatous disease

September 10, 2019
Primary immunodeficiencies are a group of over 350 rare and chronic conditions in which genetic defects cause the immune system to function improperly. Chronic…
FDA News

FDA grants breakthrough therapy designation to experimental Ebola treatment

September 9, 2019
The FDA has granted Ridgeback Biotherapeutics breakthrough therapy designation for its investigational Ebola treatment, mAb114, which was recently shown to reduce the…
More Headlines »
CME ABIM MOC

Invasive Mold Infections in the Tertiary Center: Expert Guidance on Diagnosis and Management

This activity is supported by an educational grant from Astellas Pharma Global Development, Inc.

Invasive mold infections are a significant cause of morbidity and mortality due to the increasing population of…
More »
In the Journals

Novel drug combination noninferior to meropenem for treating cUTIs

September 12, 2019
A novel combination that includes ceftriaxone, sulbactam and disodium EDTA, or CSE, was noninferior to meropenem for…
More »
Video
Meeting News

VIDEO: CDC traces unexplained bleeding outbreak to synthetic cannabinoids

May 7, 2019
More »